Abstract: A job box includes a base defining a storage area, a lid coupled to the base and moveable between an open position, in which the storage area is accessible, and a closed position, in which the storage area in not accessible, and a charging station supported by the base. The station includes a first charging port configured to charge a battery pack of a first type, a second charging port configured to charge a battery pack of a second type, a light, and a first power outlet. The charging station is moveable relative to the job box to a plurality of different positions.

Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Abstract: The present invention relates to methods and combination therapies for enhancing the activity and function of non-B cell immune cells (such as T cells) using genetically modified B cells. These methods and combinations can be used, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like.

Abstract: A metal-supported, planar cell arrangement (200) comprising at least one pair of cells (110a, 110b), each cell (110a, 110b) comprising a metal substrate (120a, 120b) having first and second sides and a porous region (124) providing fluid communication between the sides, planar cell chemistry layers (111, 112, 113) comprising fuel electrode, electrolyte, and air electrode layers being coated or deposited over, and supported by, the porous region (124) on the first side, wherein the metal substrates (120) are in a stacked arrangement with their cell chemistry layers (111, 112, 113) overlying each other such that either both their first sides, or, both their second sides face inwardly in a spaced, opposed relationship, the inwardly facing sides thereby defining a common first fluid volume (140) between them for one of fuel or oxidant.

Abstract: A stack (1) of intermediate temperature, metal-supported, solid oxide fuel cell units (10), each unit comprising a metal support substrate (12), a spacer (22) and an interconnect (30) that each have compression bolt holes (34), fuel inlet port (33), fuel outlet port (32) and air outlet (17) therein, wherein bolt voids (34) are formed by aligning the bolt holes and a further void (17) by aligning the air outlets, and the voids are vented, for example, to the environment or further void to prevent the build-up of fuel, moisture or ions.

Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

Abstract: A stack (1) of intermediate temperature, metal-supported, solid oxide fuel cell units (10), each unit comprising a metal support substrate (12), a spacer (22) and an interconnect (30) that each have compression bolt holes (34), fuel inlet port (33), fuel outlet port (32) and air outlet (17) therein, wherein bolt voids (34) are formed by aligning the bolt holes and a further void (17) by aligning the air outlets, and the voids are vented, for example, to the environment or further void to prevent the build-up of fuel, moisture or ions.

Abstract: The present invention is concerned with improved fuel cell systems and methods.

Abstract: A fuel cell system comprising a controller, a temperature sensor that has a physical presence in a conduit within the system to measure the temperature of the fluid at a point within the conduit (Tg) and a wall temperature sensor for sensing a temperature of a wall of the conduit (Tw). The controller takes Tg and Tw as inputs and applies an equation with known constants to calculate measurement error of Tg based on the local flow temperature and geometry and arrives at a calculated temperature. The equation may be applied iteratively until the difference between the calculated temperature and Tg is below an acceptable value when the calculated temperature can then be assumed to be an accurate representation of the actual gas temperature at the Tg measurement point. The direction of calculation is controlled by the relative difference between Tg and Tw.

Abstract: The present invention is concerned with improved fuel cell systems and methods.

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.

Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.

Abstract: An approach is provided for processing promotional information for facilitating a point-of-sales transaction via radio frequency (RF) memory tags. A platform causes, at least in part, a capture of promotional information from a radio frequency memory tag associated with a merchant. The tags are placed at locations including a point-of-sales terminal, store entrance or near a poster to facilitate customer access. The platform processes and/or facilitates a processing of the promotional information to present one or more offers at a device, and receives an input for selecting at least one of the one or more offers for redemption. In response, the platform causes, at least in part, a validation of the redemption of at least one of the one or more offers. The platform then causes, at least in part, a presentation of the validation at the device for a confirmation by the merchant.

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.

Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.

Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.

Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.